Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: Essential role for aggregation in neurotoxicity

Journal of Neuroscience Research

Volumn 88, Issue 15, 2010, Pages 3399-3413

  Zhao, Kelly ^a   Ippolito, Giulia ^a   Wang, Lulu ^a   Price, Valerie ^a   Kim, Mi Hwa ^a   Cornwell, Gavin ^a   Fulenchek, Stephanie ^a   Breen, Gail A ^a   Goux, Warren J ^a   D'Mello, Santosh R ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Alzheimer's disease; Neurodegenerative diseases; Neuronal cell death; Tau proteins; Tauopathies

Indexed keywords

PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALYLGLUTAMINYLISOLEUCYLVALYLLYSYLLYSINAMIDE; VALYLGLUTAMINYLISOLEUCYLVALYLPHENYLALANYLLYSINAMIDE; VALYLGLUTAMINYLVALYLVALYLTYROSYLLYSINAMIDE; VALYLGLUTAMINYLVALYLVALYLVALYLLYSINAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CYTOPLASM; DOWN REGULATION; GENE MUTATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; TAUOPATHY;

ANIMALS; BLOTTING, WESTERN; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE POTENTIAL, MITOCHONDRIAL; MUTATION; NERVE DEGENERATION; NEURONS; PEPTIDES; RATS; TAU PROTEINS; TAUOPATHIES;

EID: 78649416009     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22485     Document Type: Article

References (60)

1. Allen MJ, MacRenaris KW, Venkatasubramanian PN, Meade TJ. 2004. Cellular delivery of MRI contrast agents. Chem Biol 11:301-307.
2. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. 2006. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A 103:8864-8869.
3. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. 2005. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25:5446-5454.
4. Ballatore C, Lee VM, Trojanowski JQ. 2007. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672.
5. Barghorn S, Mandelkow E. 2002. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41:14885-14896.
6. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC. 2006. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15:433-442.
7. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C. 2007. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27:3650-3662.
8. Canu N, Dus L, Barbato C, Ciotti MT, Brancolini C, Rinaldi AM, Novak M, Cattaneo A, Bradbury A, Calissano P. 1998. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci 18:7061-7074.
9. Castellani RJ, Nunomura A, Lee HG, Perry G, Smith MA. 2008. Phosphorylated tau: toxic, protective, or none of the above. J Alzheimers Dis 14:377-383.
10. Chen HM, Wang L, D'Mello SR. 2008. Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074. J Neurochem 105:1300-1312.
11. Corsetti V, Amadoro G, Gentile A, Capsoni S, Ciotti MT, Cencioni MT, Atlante A, Canu N, Rohn TT, Cattaneo A, Calissano P. 2008. Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer's disease models. Mol Cell Neurosci 38:381-392.
12. Ding H, Johnson GV. 2008. The last tangle of tau. J Alzheimers Dis 14:441-447.
13. D'Mello SR, Galli C, Ciotti T, Calissano P. 1993. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci U S A 90:10989-10993.
14. Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, Schonig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G, Mandelkow EM. 2007. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 282:31755-31765.
15. Feany MB, Dickson DW. 1996. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 40:139-148.
16. Frost B, Jacks RL, Diamond MI. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284:12845-12852.
17. Futaki S. 2002. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int J Pharmacol 245:1-7.
18. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. 2001. Arginine-rich peptides. An abundant source of membranepermeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836-5840.
19. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. 2003. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100:10032-10037.
20. Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J. 2006. Extracellular tau is toxic to neuronal cells. FEBS Lett 580:4842-4850.
21. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras-Portugal MT, Avila J. 2008. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 37:673-681.
22. Goux WJ, Kopplin L, Nguyen AD, Leak K, Rutkofsky M, Shanmuganandam VD, Sharma D, Inouye H, Kirschner DA. 2004. The formation of straight and twisted filaments from short tau peptides. J Biol Chem 279:26868-26875.
23. Hernandez F, Avila J. 2008. Tau aggregates and tau pathology. J Alzheimers Dis 14:449-452.
24. Honson NS, Kuret J. 2008. Tau aggregation and toxicity in tauopathic neurodegenerative diseases. J Alzheimers Dis 14:417-422.
25. Jakes R, Novak M, Davison M, Wischik CM. 1991. Identification of 3-and 4-repeat tau isoforms within the PHF in Alzheimer's disease. EMBO J 10:2725-2729.
26. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. 2000. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19:5720-5728.
27. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. 2004. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279:46363-46366.
28. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. 2006. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281:1205-1214.
29. Khlistunova I, Pickhardt M, Biernat J, Wang Y, Mandelkow EM, Man-delkow E. 2007. Inhibition of tau aggregation in cell models of tauopathy. Curr Alzheimer Res 4:544-546.
30. Koulich E, Nguyen T, Johnson K, Giardina C, D'mello S. 2001. NF-kappaB is involved in the survival of cerebellar granule neurons: association of IkappaBbeta [correction of Ikappabeta] phosphorylation with cell survival. J Neurochem 76:1188-1198.
31. Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM. 2006. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 103:9673-9678.
32. Lebouvier T, Scales TM, Williamson R, Noble W, Duyckaerts C, Hanger DP, Reynolds CH, Anderton BH, Derkinderen P. 2009. The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis (in press).
33. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS. 2004. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88:554-563.
34. Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. 2008. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 68:1076-1092.
35. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM. 2008a. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 28:737-748.
36. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM. 2008b. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous tau in inducible mouse models of tauopathy. J Neurosci 28:737-748.
37. Necula M, Kuret J. 2004. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem 279:49694-49703.
38. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. 2005. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102:6990-6995.
39. Novak M, Kabat J, Wischik CM. 1993. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12:365-370.
40. Pastor MT, Kummerer N, Schubert V, Esteras-Chopo A, Dotti CG, Lopez de la Paz M, Serrano L. 2008. Amyloid toxicity is independent of polypeptide sequence, length and chirality. J Mol Biol 375:695-707.
41. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R. 2005. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A 102:10427-10432.
42. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. 2002. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99:6364-6369.
43. Reers M, Smith TW, Chen LB. 1991. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30:4480-4486.
44. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT. 2004. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23:23-34.
45. Rojas Quijano FA, Morrow D, Wise BM, Brancia FL, Goux WJ. 2006. Prediction of nucleating sequences from amyloidogenic propensities of tau-related peptides. Biochemistry 45:4638-4652.
46. Sahara N, Maeda S, Murayama M, Suzuki T, Dohmae N, Yen SH, Takashima A. 2007. Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur J Neurosci 25:3020-3029.
47. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476-481.
48. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. 1999. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38:3549-3558.
49. Singer SJ, Dewji NN. 2006. Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc Natl Acad Sci U S A 103:1546-1550.
50. Sun A, Nguyen XV, Bing G. 2002. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J Histochem Cytochem 50:463-472.
51. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. 2002. Possible existence of common internalization mechanisms among argininerich peptides. J Biol Chem 277:2437-2443.
52. Takashima A. 2008. Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy. J Alzheimers Dis 14:371-375.
53. Vauthey S, Santoso S, Gong H, Watson N, Zhang S. 2002. Molecular self-assembly of surfactant-like peptides to form nanotubes and nanovesicles. Proc Natl Acad Sci U S A 99:5355-5360.
54. Ventura S, Zurdo J, Narayanan S, Parreno M, Mangues R, Reif B, Chiti F, Giannoni E, Dobson CM, Aviles FX, Serrano L. 2004. Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc Natl Acad Sci U S A 101:7258-7263.
55. 311) forming beta structure. Proc Natl Acad Sci U S A 97:5129-5134.
56. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E. 2001. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem 276:48165-48174.
57. von Bergen M, Barghorn S, Muller SA, Pickhardt M, Biernat J, Mandelkow EM, Davies P, Aebi U, Mandelkow E. 2006. The core of taupaired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry 45:6446-6457.
58. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. 2007. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A 104:10252-10257.
59. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA. 1988a. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85:4884-4888.
60. Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A. 1988b. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85:4506-4510.